CHEMOCENTRYX, INC. 5,200,000 Shares of Common Stock Underwriting AgreementChemoCentryx, Inc. • June 11th, 2020 • Pharmaceutical preparations • New York
ChemoCentryx, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 5,200,000 shares of common stock, par value $0.001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 780,000 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
INDEMNIFICATION AGREEMENTIndemnification Agreement • January 23rd, 2012 • ChemoCentryx, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of , 20 by and between ChemoCentryx, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
CHEMOCENTRYX, INC. Shares of Common Stock Underwriting AgreementUnderwriting Agreement • January 23rd, 2012 • ChemoCentryx, Inc. • Pharmaceutical preparations • New York
CHEMOCENTRYX, INC. EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • December 4th, 2018 • ChemoCentryx, Inc. • Pharmaceutical preparations • New York
As further set forth in this agreement (this “Agreement”), ChemoCentryx, Inc., a company organized under the laws of Delaware (the “Company”), proposes to issue and sell from time to time through Piper Jaffray & Co. (the “Agent”), as sales agent, the Company’s common stock, par value $0.001 per share (the “Common Stock”) (such shares of Common Stock to be sold pursuant to this Agreement, the “Shares”) on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 2 of this Agreement on the number of shares of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agent shall have no obligation in connection with such compliance.
STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE – NET AIR COMMERCIAL REAL ESTATE ASSOCIATIONChemoCentryx, Inc. • October 14th, 2011 • Pharmaceutical preparations
EMPLOYMENT AGREEMENTEmployment Agreement • January 8th, 2018 • ChemoCentryx, Inc. • Pharmaceutical preparations • California
This Employment Agreement (“Agreement”) is made effective as of January 3rd, 2018 (“Effective Date”), by and between ChemoCentryx, Inc., a Delaware corporation (the “Company”), and Bill Fairey (“Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 12th, 2018 • ChemoCentryx, Inc. • Pharmaceutical preparations • California
This Employment Agreement (“Agreement”) is made effective as of May 2, 2016 (“Effective Date”), by and between ChemoCentryx, Inc., a Delaware corporation (the “Company”), and Rajinder Singh, D.Phil. (“Executive”).
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • January 4th, 2018 • ChemoCentryx, Inc. • Pharmaceutical preparations • California
THIS LOAN AND SECURITY AGREEMENT is made and dated as of December 28, 2017 and is entered into by and between CHEMOCENTRYX, INC., a Delaware corporation, and each of its Qualified Subsidiaries (hereinafter collectively referred to as the “Borrower”), the several banks and other financial institutions or entities from time to time parties to this Agreement (collectively, referred to as “Lender”) and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lender (in such capacity, the “Agent”).
SECOND AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 1st, 2022 • ChemoCentryx, Inc. • Pharmaceutical preparations • California
THIS SECOND AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of December 15, 2021 (the “Second Amendment Effective Date”), is entered into by and between CHEMOCENTRYX, INC., a Delaware corporation, and each of its Qualified Subsidiaries (hereinafter collectively referred to as the “Borrower”), the several banks and other financial institutions or entities from time to time party to the Loan and Security Agreement (hereinafter defined) (collectively, referred to as “Lender”), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lender (in such capacity, together with its successors and assigns in such capacity, “Agent”).
AMENDMENT NO. 1 to PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCommercialization Agreement • October 14th, 2011 • ChemoCentryx, Inc. • Pharmaceutical preparations
This Amendment No. 1 (“Amendment”) to that certain PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) entered into and made effective as of the 22nd day of August, 2006 by and between ChemoCentryx, Inc., a Delaware corporation having its principal place of business at 850 Maude Avenue, Mountain View, CA 94043 (“ChemoCentryx”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (referred to herein as “GSK”), collectively, the “Parties”, is hereby entered into by the Parties with an Amendment effective date of September 30th, 2007 (the “Amendment Effective Date”). All capitalized terms not expressly defined in this Amendment shall have the meanings given to them in the Agreement.
AMENDMENT TO SERIES D PREFERRED STOCK SUBSCRIPTION AGREEMENTSeries D Preferred Stock Subscription Agreement • October 14th, 2011 • ChemoCentryx, Inc. • Pharmaceutical preparations
This Amendment (the “Amendment”) to Series D Preferred Stock Subscription Agreement (the “Agreement”) dated as of November 8, 2007 is entered into by and between ChemoCentryx, Inc., a Delaware corporation (the “Company”) and Glaxo Group Limited, a limited liability company organized under the laws of England doing business as GlaxoSmithKline (“GSK”).
PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN GLAXO GROUP LIMITED and CHEMOCENTRYX, INC.Product Development And • January 6th, 2012 • ChemoCentryx, Inc. • Pharmaceutical preparations • Delaware
This PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is entered into and made effective as of the 22nd day of August, 2006 (the “Effective Date”) by and between ChemoCentryx, Inc., a Delaware corporation having its principal place of business at 850 Maude Avenue, Mountain View, CA 94043 (“ChemoCentryx”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (referred to herein as “GSK”). ChemoCentryx and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
Vifor (International) Ltd. Rechenstrasse 37 CH-9014 St. Gallen SwitzerlandCollaboration and License Agreement • August 9th, 2018 • ChemoCentryx, Inc. • Pharmaceutical preparations
As you know, Vifor Fresenius Medical Care Renal Pharma Ltd. (“VFMCRP”) and ChemoCentryx, Inc. (“ChemoCentryx”) are parties to that certain Collaboration and License Agreement, dated December 22, 2016 (the “VFMCRP Agreement”), pursuant to which ChemoCentryx granted VFMCRP an exclusive license to commercialize ChemoCentryx’s proprietary C5aR inhibitor known as CCX140 in certain countries. Capitalized terms used but not otherwise defined in this letter agreement (this “Letter”) will have the meanings provided in the VFMCRP Agreement. The VFMCRP Agreement was originally entered into between Vifor (International) Ltd. (“Vifor”) and ChemoCentryx and was subsequently assigned by Vifor to VFMCRP, so that references in the VFMCRP Agreement to VIT now refer to VFMCRP.
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • March 14th, 2017 • ChemoCentryx, Inc. • Pharmaceutical preparations • New York
THIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of December 22, 2016 (the “Effective Date”), by and between CHEMOCENTRYX, INC., a Delaware corporation, having an address at 850 Maude Avenue, Mountain View, CA 94043, U.S. (“ChemoCentryx”), and VIFOR (INTERNATIONAL) LTD., a corporation organized under the laws of Switzerland, having an address at Rechenstrasse 37, CH-9014 St. Gallen, Switzerland (“VIT”). ChemoCentryx and VIT may be referred to herein individually as a “Party” or collectively as the “Parties”.
CHEMOCENTRYX, INC. RESTRICTED STOCK UNIT AWARD GRANT NOTICE AND RESTRICTED STOCK UNIT AWARD AGREEMENTRestricted Stock Unit Award Agreement • August 8th, 2014 • ChemoCentryx, Inc. • Pharmaceutical preparations • Delaware
ChemoCentryx, Inc., a Delaware corporation (the “Company”), pursuant to its 2012 Equity Incentive Award Plan (as amended, the “Plan”), hereby grants to the individual listed below (“Holder”), an award of restricted stock units (“Restricted Stock Units” or “RSUs”) with respect to the number of shares of the Company’s Common Stock (the “Shares”) listed below. This award for Restricted Stock Units (this “Award”) is subject to all of the terms and conditions as set forth herein and in the Restricted Stock Unit Award Agreement attached hereto as Exhibit A (the “Restricted Stock Unit Agreement”) and the Plan, each of which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Restricted Stock Unit Agreement.
SERIES E PREFERRED STOCK SUBSCRIPTION AGREEMENTSeries E Preferred Stock Subscription Agreement • October 14th, 2011 • ChemoCentryx, Inc. • Pharmaceutical preparations • California
This Series E Preferred Stock Subscription Agreement (the “Agreement”) dated as of August 26, 2008 is entered into by and between ChemoCentryx, Inc., a Delaware corporation (the “Company”), and the individual or entity (collectively, the “Purchasers” and individually, the “Purchaser”) whose name appears on the last page of this Agreement.
amended and restated LOAN AND SECURITY AGREEMENTLoan and Security Agreement • May 11th, 2020 • ChemoCentryx, Inc. • Pharmaceutical preparations • California
THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT is made and dated as of January 8, 2020, and is entered into by and between CHEMOCENTRYX, INC., a Delaware corporation, and each of its Qualified Subsidiaries (hereinafter collectively referred to as the “Borrower”), the several banks and other financial institutions or entities from time to time parties to this Agreement (collectively, referred to as “Lender”) and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lender (in such capacity, the “Agent”), and amends and restates in its entirety that certain Loan and Security Agreement between Borrower, Lender and Agent, dated as of December 28, 2017 (as amended by that certain Amendment No. 1 to Loan and Security Agreement dated as of December 13, 2018, and as further amended, waived, or otherwise modified from time to time prior to the date hereof, the “Original Agreement”).
CHEMOCENTRYX, INC. AMENDMENT NO. 1 TO AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENTInvestors Rights Agreement • April 13th, 2016 • ChemoCentryx, Inc. • Pharmaceutical preparations • California
This Amendment No. 1 (this “Amendment”) to Amended and Restated Investors Rights Agreement, dated September 8, 2011 (the “Agreement”), is made and entered into as of April 11, 2016, by and among ChemoCentryx, Inc., a Delaware corporation (the “Company”), and the undersigned Investors and Founder of the Company.
AMENDMENT NO. 2 TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • October 14th, 2011 • ChemoCentryx, Inc. • Pharmaceutical preparations • California
THIS AMENDMENT NO. 2 TO LOAN AGREEMENT (this “Amendment”) is entered into this 19th day of April, 2010, by and between CHEMOCENTRYX, INC., a Delaware corporation (“Borrower”), and SILICON VALLEY BANK (“Bank”). Capitalized terms used herein without definition shall have the same meanings given them in the Loan Agreement (as defined below).
AMENDMENT NO. 2 to PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCommercialization Agreement • October 14th, 2011 • ChemoCentryx, Inc. • Pharmaceutical preparations
This Amendment No. 2 (“Amendment No. 2”) to that certain PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT entered into and made effective as of the 22nd day of August, 2006, and as amended by Amendment No. 1 effective as of the 30th day of September, 2007 (the “Agreement”) by and between ChemoCentryx, Inc., a Delaware corporation having its principal place of business at 850 Maude Avenue, Mountain View, CA 94043 (“ChemoCentryx”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (referred to herein as “GSK”), collectively, the “Parties”, is hereby entered into by the Parties with an Amendment No. 2 effective date of 6th day of October, 2008 (the “Amendment No. 2 Effective Date”).
AMENDMENT TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • August 9th, 2018 • ChemoCentryx, Inc. • Pharmaceutical preparations
This AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT (the “Amendment”) is effective as of June 6, 2018 (the “Amendment Effective Date”) by and between CHEMOCENTRYX, INC., a Delaware corporation, having an address at 850 Maude Avenue, Mountain View, CA 94043, U.S. (“ChemoCentryx”), and VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD., a corporation organized under the laws of Switzerland, having an address at Rechenstrasse 37, CH-9014 St. Gallen, Switzerland (“VFMCRP”). ChemoCentryx and VFMCRP may be referred to herein individually as a “Party” or collectively as the “Parties”.
COMMERCIAL MANUFACTURING AGREEMENT (AVACOPAN)Commercial Manufacturing Agreement • November 9th, 2020 • ChemoCentryx, Inc. • Pharmaceutical preparations
THIS AGREEMENT (“Agreement”) is made and entered into as of August 17, 2020 (the “Effective Date”) by and between ChemoCentryx, Inc. a Delaware corporation, with offices at 850 Maude Avenue, Mountain View, CA 94043 (“Customer”), and Hovione LLC, with a mailing address at 40 Lake Drive, East Windsor, New Jersey 08520 (“Hovione”).
Manufacturing and Supply AgreementManufacturing and Supply Agreement • March 1st, 2021 • ChemoCentryx, Inc. • Pharmaceutical preparations • New York
WHEREAS CCX is a pharmaceutical company that is commercialising the Product (as defined in the License Agreement) and has licensed VF to conduct studies and commercialize the Product in certain countries pursuant to that certain Collaboration and License Agreement between CCX and VF’s affiliate, Vifor (International) Ltd., dated May 9, 2016 (as amended from time to time, the “License Agreement”). The License Agreement was assigned by Vifor (International) Ltd. to VF on December 30, 2016.
CONVERTIBLE NOTE LOAN AGREEMENTConvertible Note Loan Agreement • October 14th, 2011 • ChemoCentryx, Inc. • Pharmaceutical preparations • Delaware
FOR VALUE RECEIVED, THE SUFFICIENCY OF WHICH IS HEREBY ACKNOWLEDGED, the undersigned, CHEMOCENTRYX, INC., a Delaware corporation (together with its permitted successors and assigns, the “Borrower”), hereby executes this Convertible Note Loan Agreement (the “Note”) and unconditionally promises to pay to the order of TECHNE CORPORATION, a Minnesota corporation (together with its permitted successors and assigns, the “Holder”), the principal sum of TEN MILLION U.S. DOLLARS (U.S. $10,000,000), subject to adjustment as set forth herein, on the Maturity Date (as defined below), unless earlier paid or converted in accordance with the terms hereof and Holder agrees to satisfy its obligations as set forth herein. Capitalized terms used herein and not otherwise defined shall have the meanings they were assigned to have in Section 12 hereof.
PRODUCT AGREEMENT (Includes Schedules A to D) PRODUCT AGREEMENTProduct Agreement • August 10th, 2020 • ChemoCentryx, Inc. • Pharmaceutical preparations • Delaware
This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated March 18, 2020 between Patheon Pharmaceuticals Inc., and ChemoCentryx, Inc., (the “Master Agreement”), and is entered into as of the last signature date set forth below (the “Effective Date”), between Patheon Pharmaceuticals Inc., a corporation existing under the laws of the State of Delaware, having a principal place of business at 2110 East Galbraith Road, Cincinnati, OH 45237-1625 (“Patheon”) and ChemoCentryx, Inc., a corporation existing under the laws of the State of Delaware having a principal place of business at 850 Maude Avenue, Mountain View, CA 94043 USA (“Client”).
AMENDMENT NO. 3 to PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCommercialization Agreement • October 14th, 2011 • ChemoCentryx, Inc. • Pharmaceutical preparations
This Amendment No. 3 (“Amendment No. 3”) to that certain PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT entered into and made effective as of the 22nd day of August, 2006, and as amended by Amendment No. 1 effective as of the 30th day of September, 2007, and by Amendment No. 2 effective as of the 6th day of October, 2008 (the “Agreement”), by and between ChemoCentryx, Inc., a Delaware corporation having its principal place of business at 850 Maude Avenue, Mountain View, CA 94043 (“ChemoCentryx”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (referred to herein as “GSK”), collectively, the “Parties”, is hereby entered into by the Parties with an Amendment No. 3 effective date of August 22nd, 2009 (the “Amendment No. 3 Effective Date”).
THIRD AMENDMENT TO LEASELease • August 5th, 2019 • ChemoCentryx, Inc. • Pharmaceutical preparations
THIS THIRD AMENDMENT TO LEASE (this “Amendment”) is made and entered into as of April 5, 2019 but effective as of May 1, 2019 (the “Effective Date”), by and between GOOGLE LLC, a Delaware limited liability company (“Landlord” or “Lessor”), and CHEMOCENTRYX, INC., a Delaware corporation (“Tenant” or “Lessee”).
AMENDMENT NO. 5 to PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCommercialization Agreement • October 14th, 2011 • ChemoCentryx, Inc. • Pharmaceutical preparations
This Amendment No. 5 (“Amendment No. 5”) to that certain PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT entered into and made effective as of the 22nd day of August, 2006, and as amended by Amendment No. 1 effective as of the 30th day of September, 2007, by Amendment No. 2 effective as of the 6th day of October 2008, by Amendment No. 3 effective as of the 22nd day of August 2009, and by Amendment No. 4 effective as of the 26th day of February, 2010 (the “Agreement”) by and between ChemoCentryx, Inc., a Delaware corporation having its principal place of business at 850 Maude Avenue, Mountain View, CA 94043 (“ChemoCentryx”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (referred to herein as “GSK”), collectively, the “Parties”, is hereby entered into by the Parties with an Amendment No. 5 effective date of November 15, 2010 (the “Amendment
First Amendment to Lease AgreementTo Lease Agreement • November 13th, 2012 • ChemoCentryx, Inc. • Pharmaceutical preparations
This First Amendment to Lease Agreement (the “Amendment”) Is dated August 16, 2012, for reference purposes only, and is entered Into by and between Portola Land Company, a California limited partnership (“Lessor”), and ChemoCentryx, a Delaware corporation (“Lessee”), with reference to the following facts.
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • October 14th, 2011 • ChemoCentryx, Inc. • Pharmaceutical preparations • Delaware
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of the Effective Date between SILICON VALLEY BANK, a California corporation (“Bank”), and CHEMOCENTRYX, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:
AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 11th, 2019 • ChemoCentryx, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT (the “First Amendment”) is dated as of December 13, 2018 (the “First Amendment Date”) and is entered into by and among CHEMOCENTRYX, INC., a Delaware corporation, the several banks and other financial institutions or entities from time to time parties hereto (collectively, referred to as “Lender”) and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent for itself and the Lender (in such capacity, the “Agent”). Capitalized terms used herein without definition shall have the same meanings given them in the Loan Agreement (as defined below).
AMENDMENT TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • August 8th, 2017 • ChemoCentryx, Inc. • Pharmaceutical preparations
This AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT (the “Amendment”) is effective as of May 22, 2017 (the “Amendment Effective Date”) by and between CHEMOCENTRYX, INC., a Delaware corporation, having an address at 850 Maude Avenue, Mountain View, CA 94043, U.S. (“ChemoCentryx”), and VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD., a corporation organized under the laws of Switzerland, having an address at Rechenstrasse 37, CH-9014 St. Gallen, Switzerland (“VFMCRP”). ChemoCentryx and VFMCRP may be referred to herein individually as a “Party” or collectively as the “Parties”.
PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN GLAXO GROUP LIMITED and CHEMOCENTRYX, INC.Product Development And • December 20th, 2007 • ChemoCentryx, Inc. • Pharmaceutical preparations • Delaware
This PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is entered into and made effective as of the 22nd day of August, 2006 (the “Effective Date”) by and between ChemoCentryx, Inc., a Delaware corporation having its principal place of business at 850 Maude Avenue, Mountain View, CA 94043 (“ChemoCentryx”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (referred to herein as “GSK”). ChemoCentryx and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
RIGHT TO INVEST AGREEMENTRight to Invest Agreement • May 11th, 2020 • ChemoCentryx, Inc. • Pharmaceutical preparations
THIS RIGHT TO INVEST AGREEMENT (this “Agreement”) is made as of January 8, 2020, by and between ChemoCentryx, Inc., a Delaware corporation (“ChemoCentryx”) and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as a Lender (in such capacity, the “Lender”).
CHEMOCENTRYX, INC. STOCK PURCHASE AGREEMENTStock Purchase Agreement • August 9th, 2016 • ChemoCentryx, Inc. • Pharmaceutical preparations
THIS STOCK PURCHASE AGREEMENT (“Agreement”) is made as of May 9, 2016 by and between CHEMOCENTRYX, INC., a Delaware corporation (the “Company”), and VIFOR (INTERNATIONAL) LTD., a corporation organized under the laws of Switzerland (the “Purchaser”). Capitalized terms used but not defined herein shall have the meaning given to them in that certain Collaboration and License Agreement (the “Collaboration and License Agreement”), dated as of the date hereof, entered into between the Company and the Purchaser.
